Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
IQVIA HoldingsLTS:0JDM +12.23%86 Debt-to-EBITDA is 4.97 as of Mar. 2026, which is 5% below its 10-year median of 5.22. GuruFocus rates LTS:0JDM with a GF Score™ of 86/100 and a GF Value™ of $245.43 (Fairly Valued). The stock has 7 warning signs investors should review. Among 113 Medical Diagnostics & Research companies, IQVIA Holdings ranks worse than 78.76% on this metric.
Debt-to-EBITDA measures a company's ability to pay off its debt.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
The historical rank and industry rank for IQVIA Holdings's Debt-to-EBITDA or its related term are showing as below:
LTS:0JDM'
s Debt-to-EBITDA Range Over the Past 10 Years
Min: 4.1 Med: 5.22 Max: 8.48
Current: 4.57
During the past 13 years, the highest Debt-to-EBITDA Ratio of IQVIA Holdings was 8.48. The lowest was 4.10. And the median was 5.22.
LTS:0JDM's Debt-to-EBITDA is ranked worse than 78.76% of 113
companies
in the Medical Diagnostics & Research industry
Industry Median: 2.32
vs LTS:0JDM: 4.57
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
IQVIA Holdings Debt-to-EBITDA Related Terms
IQVIA Holdings Debt-to-EBITDA Historical Data
* Premium members only.
The historical data trend for IQVIA Holdings's Debt-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
LTS:0JDM vs WAT, NTRA, A: Debt-to-EBITDA Comparison
For the Diagnostics & Research subindustry, IQVIA Holdings's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
IQVIA Holdings Debt-to-EBITDA vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, IQVIA Holdings's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where IQVIA Holdings's Debt-to-EBITDA falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is four times the quarterly (Mar. 2026) EBITDA data.
IQVIA Holdings (LTS:0JDM) has a Debt-to-EBITDA of 4.97 as of Mar. 2026. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on IQVIA Holdings. This is near median its historical median of 5.22. Over the past decade, IQVIA Holdings' Debt-to-EBITDA has ranged from 4.10 to 8.48. According to the industry distribution chart, IQVIA Holdings ranks #89 out of 113 companies in the Medical Diagnostics & Research industry, placing it in the top 78.8%.
Is IQVIA Holdings' Debt-to-EBITDA too high?
IQVIA Holdings' current Debt-to-EBITDA of 4.97 is near median its 10-year median of 5.22. Over the past 10 years, this metric has ranged from a low of 4.10 to a high of 8.48. The Medical Diagnostics & Research industry median Debt-to-EBITDA is 2.32. IQVIA Holdings' value of 4.97 is 114.2% above this industry median. Based on the distribution chart, IQVIA Holdings ranks #89 out of 113 companies in the Medical Diagnostics & Research industry, which is in the bottom quartile relative to peers. Overall, IQVIA Holdings has a GF Score™ of 86/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does IQVIA Holdings' Debt-to-EBITDA compare to WAT and NTRA?
According to the Medical Diagnostics & Research industry distribution chart, IQVIA Holdings ranks #89 out of 113 companies for Debt-to-EBITDA. This places IQVIA Holdings in the lower half of its industry. The industry median Debt-to-EBITDA is 2.32. IQVIA Holdings' value of 4.97 is 114.2% above this benchmark. Historically, IQVIA Holdings' own Debt-to-EBITDA has ranged from 4.10 to 8.48 over the past decade. While the company's 10-year median is 5.22 vs. the industry median of 2.32, IQVIA Holdings has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Medical Diagnostics & Research company?
The median Debt-to-EBITDA among Medical Diagnostics & Research companies is 2.32, based on 113 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. IQVIA Holdings's current Debt-to-EBITDA of 4.97 is 114.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on IQVIA Holdings. For the Medical Diagnostics & Research industry, the median Debt-to-EBITDA is 2.32 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. IQVIA Holdings's current Debt-to-EBITDA is 4.97, which is near median its own 10-year median of 5.22. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is IQVIA Holdings stock overvalued right now?
Based on GuruFocus' analysis, IQVIA Holdings (LTS:0JDM) is currently considered Fairly Valued. The stock's GF Value™ is $245.43, compared to a current price of $238.00 — trading 3% below its estimated fair value. The current Debt-to-EBITDA is 4.97, which is near median its 10-year median of 5.22 and 114.2% above the Medical Diagnostics & Research industry median of 2.32. IQVIA Holdings' overall GF Score™ is 86/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For IQVIA Holdings (LTS:0JDM), the current Debt-to-EBITDA is 4.97 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is IQVIA Holdings (LTS:0JDM) Overvalued in 2026?
Based on GuruFocus' analysis, IQVIA Holdings stock appears to be undervalued.
The current stock price of $238.00 is trading 3% below its estimated GF Value™ of $245.43.
GuruFocus considers IQVIA Holdings to be Fairly Valued.
Key valuation signals for LTS:0JDM:
Debt-to-EBITDA: 4.97 (near median its 10-year median of 5.22)
GF Value™: $245.43 vs. price of $238.00 (3% below fair value)
Industry Position: 114.2% above the Medical Diagnostics & Research median (#89 of 113)
No single metric tells the full story. See the LTS:0JDM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Iqvia is a global leader in clinical research and technology solutions for the life science industry. Formed in 2016 from the merger of Quintiles and IMS Health, it combined clinical trial services with extensive healthcare data and analytics. Its research and development solutions segment provides outsourced clinical development services spanning drug discovery, trial design, patient recruitment, site management, clinical testing, real-world studies, and the regulatory approval process. Its commercial solutions segment helps companies optimize product commercialization through analytics, technology, and outsourced sales and medical services. Together, Iqvia supports customers across the life science industry, and it serves biopharmaceutical firms, providers, payers, and policymakers.
86GF Score
Get the complete analysis for LTS:0JDM
Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LTS:0JDM has been successfully added to your 
